array(40) {
["request_overridden_res"]=>
string(1) "3"
["project_status"]=>
string(30) "approved_pending_dua_signature"
["project_assoc_trials"]=>
array(17) {
[0]=>
object(WP_Post)#5855 (24) {
["ID"]=>
int(17826)
["post_author"]=>
string(4) "1885"
["post_date"]=>
string(19) "2025-08-27 10:09:20"
["post_date_gmt"]=>
string(19) "2025-08-27 14:09:20"
["post_content"]=>
string(0) ""
["post_title"]=>
string(244) "NCT04599855 - A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(191) "nct04599855-a-randomized-double-blind-multicenter-placebo-controlled-study-to-evaluate-the-efficacy-safety-and-tolerability-of-esketamine-nasal-spray-administered-as-monotherapy-in-adult-part"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-09-30 12:50:59"
["post_modified_gmt"]=>
string(19) "2025-09-30 16:50:59"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(60) "https://yoda.yale.edu/?post_type=clinical_trial&p=17826"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[1]=>
object(WP_Post)#5856 (24) {
["ID"]=>
int(17528)
["post_author"]=>
string(4) "1885"
["post_date"]=>
string(19) "2025-06-23 17:11:46"
["post_date_gmt"]=>
string(19) "2025-06-23 21:11:46"
["post_content"]=>
string(0) ""
["post_title"]=>
string(292) "NCT04338321 - A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(188) "nct04338321-a-long-term-comparison-of-esketamine-nasal-spray-versus-quetiapine-extended-release-both-in-combination-with-a-selective-serotonin-reuptake-inhibitor-serotonin-norepinephrine-r"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-12-16 12:40:07"
["post_modified_gmt"]=>
string(19) "2025-12-16 17:40:07"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(60) "https://yoda.yale.edu/?post_type=clinical_trial&p=17528"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[2]=>
object(WP_Post)#5857 (24) {
["ID"]=>
int(13161)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2023-08-09 22:12:42"
["post_date_gmt"]=>
string(19) "2023-08-09 22:12:42"
["post_content"]=>
string(0) ""
["post_title"]=>
string(270) "NCT03434041 - A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(196) "nct03434041-a-randomized-double-blind-multicenter-active-controlled-study-to-evaluate-the-efficacy-pharmacokinetics-safety-and-tolerability-of-flexible-doses-of-intranasal-esketamine-plus-an-ora-2"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-05-13 16:44:03"
["post_modified_gmt"]=>
string(19) "2025-05-13 20:44:03"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(245) "https://dev-yoda.pantheonsite.io/clinical-trial/nct03434041-a-randomized-double-blind-multicenter-active-controlled-study-to-evaluate-the-efficacy-pharmacokinetics-safety-and-tolerability-of-flexible-doses-of-intranasal-esketamine-plus-an-ora-2/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[3]=>
object(WP_Post)#5858 (24) {
["ID"]=>
int(1907)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2023-08-05 04:45:19"
["post_date_gmt"]=>
string(19) "2023-08-05 04:45:19"
["post_content"]=>
string(0) ""
["post_title"]=>
string(124) "NCT02497287 - An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(120) "nct02497287-an-open-label-long-term-safety-and-efficacy-study-of-intranasal-esketamine-in-treatment-resistant-depression"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-05-13 16:38:44"
["post_modified_gmt"]=>
string(19) "2025-05-13 20:38:44"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(169) "https://dev-yoda.pantheonsite.io/clinical-trial/nct02497287-an-open-label-long-term-safety-and-efficacy-study-of-intranasal-esketamine-in-treatment-resistant-depression/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[4]=>
object(WP_Post)#5859 (24) {
["ID"]=>
int(1908)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2023-08-05 04:45:19"
["post_date_gmt"]=>
string(19) "2023-08-05 04:45:19"
["post_content"]=>
string(0) ""
["post_title"]=>
string(188) "NCT02493868 - A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(183) "nct02493868-a-randomized-double-blind-multicenter-active-controlled-study-of-intranasal-esketamine-plus-an-oral-antidepressant-for-relapse-prevention-in-treatment-resistant-depression"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-05-13 16:39:21"
["post_modified_gmt"]=>
string(19) "2025-05-13 20:39:21"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(232) "https://dev-yoda.pantheonsite.io/clinical-trial/nct02493868-a-randomized-double-blind-multicenter-active-controlled-study-of-intranasal-esketamine-plus-an-oral-antidepressant-for-relapse-prevention-in-treatment-resistant-depression/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[5]=>
object(WP_Post)#5861 (24) {
["ID"]=>
int(1913)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2023-08-05 04:45:19"
["post_date_gmt"]=>
string(19) "2023-08-05 04:45:19"
["post_content"]=>
string(0) ""
["post_title"]=>
string(226) "NCT02918318 - A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(194) "nct02918318-a-randomized-double-blind-multicenter-placebo-controlled-study-to-evaluate-the-efficacy-safety-and-tolerability-of-fixed-doses-of-intranasal-esketamine-in-japanese-subjects-with-trea"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-05-13 16:42:24"
["post_modified_gmt"]=>
string(19) "2025-05-13 20:42:24"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(243) "https://dev-yoda.pantheonsite.io/clinical-trial/nct02918318-a-randomized-double-blind-multicenter-placebo-controlled-study-to-evaluate-the-efficacy-safety-and-tolerability-of-fixed-doses-of-intranasal-esketamine-in-japanese-subjects-with-trea/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[6]=>
object(WP_Post)#5863 (24) {
["ID"]=>
int(1917)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2023-08-05 04:45:19"
["post_date_gmt"]=>
string(19) "2023-08-05 04:45:19"
["post_content"]=>
string(0) ""
["post_title"]=>
string(172) "NCT01640080 - A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects With Treatment-Resistant Depression"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(168) "nct01640080-a-double-blind-double-randomization-placebo-controlled-study-of-the-efficacy-of-intravenous-esketamine-in-adult-subjects-with-treatment-resistant-depression"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-07-24 09:42:03"
["post_modified_gmt"]=>
string(19) "2025-07-24 13:42:03"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(217) "https://dev-yoda.pantheonsite.io/clinical-trial/nct01640080-a-double-blind-double-randomization-placebo-controlled-study-of-the-efficacy-of-intravenous-esketamine-in-adult-subjects-with-treatment-resistant-depression/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[7]=>
object(WP_Post)#5865 (24) {
["ID"]=>
int(1912)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2021-03-04 15:30:00"
["post_date_gmt"]=>
string(19) "2021-03-04 15:30:00"
["post_content"]=>
string(0) ""
["post_title"]=>
string(334) "NCT03097133 - A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(196) "nct03097133-a-double-blind-randomized-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-intranasal-esketamine-in-addition-to-comprehensive-standard-of-care-for-the-rapid-reduction-of"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-05-13 16:41:54"
["post_modified_gmt"]=>
string(19) "2025-05-13 20:41:54"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(245) "https://dev-yoda.pantheonsite.io/clinical-trial/nct03039192-a-double-blind-randomized-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-intranasal-esketamine-in-addition-to-comprehensive-standard-of-care-for-the-rapid-reduction-of/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[8]=>
object(WP_Post)#5866 (24) {
["ID"]=>
int(1910)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2021-03-04 15:28:00"
["post_date_gmt"]=>
string(19) "2021-03-04 15:28:00"
["post_content"]=>
string(0) ""
["post_title"]=>
string(290) "NCT02133001 - A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Who Are Assessed to be at Imminent Risk for Suicide"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(195) "nct02133001-a-double-blind-randomized-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-intranasal-esketamine-for-the-rapid-reduction-of-the-symptoms-of-major-depressive-disorder-in"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-05-13 16:40:22"
["post_modified_gmt"]=>
string(19) "2025-05-13 20:40:22"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(244) "https://dev-yoda.pantheonsite.io/clinical-trial/nct02133001-a-double-blind-randomized-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-intranasal-esketamine-for-the-rapid-reduction-of-the-symptoms-of-major-depressive-disorder-in/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[9]=>
object(WP_Post)#5867 (24) {
["ID"]=>
int(1911)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2021-03-01 19:37:00"
["post_date_gmt"]=>
string(19) "2021-03-01 19:37:00"
["post_content"]=>
string(0) ""
["post_title"]=>
string(334) "NCT03039192 - A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(198) "nct03039192-a-double-blind-randomized-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-intranasal-esketamine-in-addition-to-comprehensive-standard-of-care-for-the-rapid-reduction-of-2"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-05-13 16:40:50"
["post_modified_gmt"]=>
string(19) "2025-05-13 20:40:50"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(244) "https://dev-yoda.pantheonsite.io/clinical-trial/nct03097133-a-double-blind-randomized-placebo-controlled-study-to-evaluate-the-efficacy-and-safety-of-intranasal-esketamine-in-addition-to-comprehensive-standard-of-care-for-the-rapid-reduction-o/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[10]=>
object(WP_Post)#5868 (24) {
["ID"]=>
int(1906)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2021-03-01 13:27:00"
["post_date_gmt"]=>
string(19) "2021-03-01 13:27:00"
["post_content"]=>
string(0) ""
["post_title"]=>
string(238) "NCT02422186 - A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(193) "nct02422186-a-randomized-double-blind-multicenter-active-controlled-study-to-evaluate-the-efficacy-safety-and-tolerability-of-intranasal-esketamine-plus-an-oral-antidepressant-in-elderly-subjec"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-10-21 10:39:24"
["post_modified_gmt"]=>
string(19) "2025-10-21 14:39:24"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(242) "https://dev-yoda.pantheonsite.io/clinical-trial/nct02422186-a-randomized-double-blind-multicenter-active-controlled-study-to-evaluate-the-efficacy-safety-and-tolerability-of-intranasal-esketamine-plus-an-oral-antidepressant-in-elderly-subjec/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[11]=>
object(WP_Post)#5860 (24) {
["ID"]=>
int(1909)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2023-08-05 04:45:19"
["post_date_gmt"]=>
string(19) "2023-08-05 04:45:19"
["post_content"]=>
string(0) ""
["post_title"]=>
string(206) "NCT01998958 - A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(195) "nct01998958-a-double-blind-doubly-randomized-placebo-controlled-study-of-intranasal-esketamine-in-an-adaptive-treatment-protocol-to-assess-safety-and-efficacy-in-treatment-resistant-depression-sy"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2026-10-02 13:48:46"
["post_modified_gmt"]=>
string(19) "2026-10-02 17:48:46"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(244) "https://dev-yoda.pantheonsite.io/clinical-trial/nct01998958-a-double-blind-doubly-randomized-placebo-controlled-study-of-intranasal-esketamine-in-an-adaptive-treatment-protocol-to-assess-safety-and-efficacy-in-treatment-resistant-depression-sy/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[12]=>
object(WP_Post)#5869 (24) {
["ID"]=>
int(1905)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2021-03-01 13:22:00"
["post_date_gmt"]=>
string(19) "2021-03-01 13:22:00"
["post_content"]=>
string(0) ""
["post_title"]=>
string(254) "NCT02418585 - A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(193) "nct02418585-a-randomized-double-blind-multicenter-active-controlled-study-to-evaluate-the-efficacy-safety-and-tolerability-of-flexible-doses-of-intranasal-esketamine-plus-an-oral-antidepressant"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-05-13 16:36:54"
["post_modified_gmt"]=>
string(19) "2025-05-13 20:36:54"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(242) "https://dev-yoda.pantheonsite.io/clinical-trial/nct02418585-a-randomized-double-blind-multicenter-active-controlled-study-to-evaluate-the-efficacy-safety-and-tolerability-of-flexible-doses-of-intranasal-esketamine-plus-an-oral-antidepressant/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[13]=>
object(WP_Post)#5870 (24) {
["ID"]=>
int(1904)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2021-03-01 12:58:00"
["post_date_gmt"]=>
string(19) "2021-03-01 12:58:00"
["post_content"]=>
string(0) ""
["post_title"]=>
string(251) "NCT02417064 - A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(193) "nct02417064-a-randomized-double-blind-multicenter-active-controlled-study-to-evaluate-the-efficacy-safety-and-tolerability-of-fixed-doses-of-intranasal-esketamine-plus-an-oral-antidepressant-in"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-05-13 16:35:55"
["post_modified_gmt"]=>
string(19) "2025-05-13 20:35:55"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(242) "https://dev-yoda.pantheonsite.io/clinical-trial/nct02417064-a-randomized-double-blind-multicenter-active-controlled-study-to-evaluate-the-efficacy-safety-and-tolerability-of-fixed-doses-of-intranasal-esketamine-plus-an-oral-antidepressant-in/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[14]=>
object(WP_Post)#5862 (24) {
["ID"]=>
int(1916)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2023-08-05 04:45:19"
["post_date_gmt"]=>
string(19) "2023-08-05 04:45:19"
["post_content"]=>
string(0) ""
["post_title"]=>
string(158) "NCT01627782 - A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(152) "nct01627782-a-double-blind-randomized-placebo-controlled-parallel-group-dose-frequency-study-of-ketamine-in-subjects-with-treatment-resistant-depression"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-06-26 11:03:35"
["post_modified_gmt"]=>
string(19) "2025-06-26 15:03:35"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(201) "https://dev-yoda.pantheonsite.io/clinical-trial/nct01627782-a-double-blind-randomized-placebo-controlled-parallel-group-dose-frequency-study-of-ketamine-in-subjects-with-treatment-resistant-depression/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[15]=>
object(WP_Post)#5871 (24) {
["ID"]=>
int(1604)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2017-08-24 12:58:00"
["post_date_gmt"]=>
string(19) "2017-08-24 12:58:00"
["post_content"]=>
string(0) ""
["post_title"]=>
string(204) "NCT00044681 - A Study to Evaluate the Efficacy, Safety and Maintenance Effect of Risperidone Augmentation of SSRI Monotherapy in Young and Older Adult Patients With Unipolar Treatment-Resistant Depression"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(197) "nct00044681-a-study-to-evaluate-the-efficacy-safety-and-maintenance-effect-of-risperidone-augmentation-of-ssri-monotherapy-in-young-and-older-adult-patients-with-unipolar-treatment-resistant-depres"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2025-06-25 13:28:29"
["post_modified_gmt"]=>
string(19) "2025-06-25 17:28:29"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(246) "https://dev-yoda.pantheonsite.io/clinical-trial/nct00044681-a-study-to-evaluate-the-efficacy-safety-and-maintenance-effect-of-risperidone-augmentation-of-ssri-monotherapy-in-young-and-older-adult-patients-with-unipolar-treatment-resistant-depres/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
[16]=>
object(WP_Post)#5864 (24) {
["ID"]=>
int(1915)
["post_author"]=>
string(4) "1363"
["post_date"]=>
string(19) "2021-04-02 12:24:00"
["post_date_gmt"]=>
string(19) "2021-04-02 12:24:00"
["post_content"]=>
string(0) ""
["post_title"]=>
string(154) "NCT00095134 - A Double-Blind Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is not Responding to Standard Therapy"
["post_excerpt"]=>
string(0) ""
["post_status"]=>
string(7) "publish"
["comment_status"]=>
string(6) "closed"
["ping_status"]=>
string(6) "closed"
["post_password"]=>
string(0) ""
["post_name"]=>
string(152) "nct00095134-a-double-blind-study-comparing-adjunctive-risperidone-versus-placebo-in-major-depressive-disorder-that-is-not-responding-to-standard-therapy"
["to_ping"]=>
string(0) ""
["pinged"]=>
string(0) ""
["post_modified"]=>
string(19) "2026-05-05 10:34:12"
["post_modified_gmt"]=>
string(19) "2026-05-05 14:34:12"
["post_content_filtered"]=>
string(0) ""
["post_parent"]=>
int(0)
["guid"]=>
string(201) "https://dev-yoda.pantheonsite.io/clinical-trial/nct00095134-a-double-blind-study-comparing-adjunctive-risperidone-versus-placebo-in-major-depressive-disorder-that-is-not-responding-to-standard-therapy/"
["menu_order"]=>
int(0)
["post_type"]=>
string(14) "clinical_trial"
["post_mime_type"]=>
string(0) ""
["comment_count"]=>
string(1) "0"
["filter"]=>
string(3) "raw"
}
}
["project_title"]=>
string(142) "Symptom-Specific Changes and Prediction of Clinical Response in Esketamine/Ketamine and Antipsychotic Trials of Treatment-Resistant Depression"
["project_narrative_summary"]=>
string(865) "This study will use individual participant data (IPD) from randomized, placebo-controlled and open label trials of esketamine/ketamine and antipsychotics for treatment-resistant depression to investigate whether examining changes in individual depressive symptoms provides clinically useful information beyond conventional total depression severity scores.
The study will evaluate whether early changes in individual symptoms improve the prediction of subsequent response and remission beyond baseline characteristics and early changes in total depression severity. Where comparable measures are available, the study will also examine whether symptom improvement corresponds to functional recovery.
The goal is to determine whether more detailed symptom-level information can enhance the evaluation of clinically meaningful treatment outcomes.
"
["project_learn_source"]=>
string(9) "colleague"
["principal_investigator"]=>
array(7) {
["first_name"]=>
string(5) "Ramin"
["last_name"]=>
string(8) "Mojtabai"
["degree"]=>
string(12) "MD, PhD, MPH"
["primary_affiliation"]=>
string(17) "Tulane University"
["email"]=>
string(20) "rmojtabai@tulane.edu"
["state_or_province"]=>
string(2) "LA"
["country"]=>
string(13) "United States"
}
["project_key_personnel"]=>
array(2) {
[0]=>
array(6) {
["p_pers_f_name"]=>
string(5) "Ryoko"
["p_pers_l_name"]=>
string(8) "Susukida"
["p_pers_degree"]=>
string(3) "PhD"
["p_pers_pr_affil"]=>
string(47) "Johns Hopkins Bloomberg School of Public Health"
["p_pers_scop_id"]=>
string(11) "56601412000"
["requires_data_access"]=>
string(3) "yes"
}
[1]=>
array(6) {
["p_pers_f_name"]=>
string(8) "Masoumeh"
["p_pers_l_name"]=>
string(12) "Aminesmaeili"
["p_pers_degree"]=>
string(7) "MD, MPH"
["p_pers_pr_affil"]=>
string(47) "Johns Hopkins Bloomberg School of Public Health"
["p_pers_scop_id"]=>
string(11) "34876281500"
["requires_data_access"]=>
string(3) "yes"
}
}
["project_ext_grants"]=>
array(2) {
["value"]=>
string(2) "no"
["label"]=>
string(68) "No external grants or funds are being used to support this research."
}
["project_date_type"]=>
string(18) "full_crs_supp_docs"
["property_scientific_abstract"]=>
string(1629) "Background: Both esketamine/ketamine and antipsychotic medications are increasingly used in management of TRD. The efficacy of these treatments is commonly evaluated using changes in total depression severity scores. Total scores may obscure differences in treatment effects across individual symptoms and may not capture all clinically relevant dimensions of recovery. Whether early symptom-specific changes provide useful information about subsequent treatment outcomes beyond conventional total scores remains an important question.
Objective: To determine whether early symptom-level changes improve the prediction of subsequent clinical response and remission beyond total depression severity scores. Secondary objectives are to examine the relationship between symptom improvement and functional recovery, heterogeneity of symptom responses and examine the network of symptoms before and after treatment.
Study Design: One-stage individual participant data meta-analysis.
Participants: Adult participants in eligible randomized controlled trials and open-label trials.
Primary and Secondary Outcomes: The primary outcomes will be symptom-specific changes measured using individual items of the Montgomery–Asberg Depression Rating Scale (MADRS). Secondary outcomes include functional impairment, comorbidity and health-related quality of life, where comparable measures are available.
Statistical Analysis: Longitudinal mixed-effects models for predictive analysis, estimation of conditional average treatment effect for heterogeneity in symptom responses, network analysis of symptoms."
["project_brief_bg"]=>
string(3222) "Esketamine, a noncompetitive NMDA receptor antagonist, was FDA-approved in 2019 for use with an oral antidepressant in treatment-resistant depression (TRD), and in 2025 as monotherapy for TRD patients inadequately responsive to two antidepressants.1,2 Multiple randomized trials have evaluated esketamine for TRD.3-11 Several second-generation antipsychotics are also approved as adjunctive MDD treatments after inadequate antidepressant response.12-16 Most efficacy analyses rely on total MADRS score changes,3,5-8,12-16 with response/remission defined by prespecified severity thresholds.17-19 While clinically established, total scores can obscure differences in how patients' symptoms improve.
Depressive symptoms are heterogeneous: patients with similar reductions in total severity may differ markedly in mood, anhedonia, concentration, sleep, and appetite.20-23 Characterizing symptom-specific treatment effects may offer a more detailed picture of esketamine's clinical effects.
Prior work examined individual MADRS/PHQ-9 item changes in an esketamine TRD trial10 and sex differences in symptom-domain response.24 However, it remains unclear whether early symptom-specific changes add predictive information about subsequent response/remission beyond early changes in total severity, and whether this generalizes across trials. Symptom-level associations with outcomes do not necessarily indicate differential treatment effects—they may reflect general improvement, placebo response, baseline severity, or other prognostic factors. Analyses must separate prediction of outcomes from estimation of differential treatment effects. A related question is whether symptom improvement corresponds to functional recovery.
Some studies suggest individual symptom analysis adds little predictive value beyond early overall improvement in MDD generally,25,26 though patients vary substantially in which symptoms respond first.26 Symptom-specific response in TRD has rarely been studied. One IV ketamine study found the largest early effect on sadness, with suicidal symptom improvement emerging later.27 The study also found strengthened interrelationships among residual symptoms. Another found suicidal ideation and mood showed the largest response and appetite the least.28
Individual trials can evaluate symptom-specific effects but are limited by small samples, narrow treatment ranges, and inability to test reproducibility. An individual participant data meta-analysis of esketamine/ketamine and antipsychotic trials offers the chance to examine symptom-specific effects and trajectories in a larger, diverse population; test whether patterns are consistent across trials; and determine whether early symptom changes add predictive value beyond total depression scores in TRD. Combining participant- and trial-level data allows assessment of cross-study consistency, ruling out effects driven by specific populations or settings.
This study complements existing evaluations of average treatment efficacy and treatment-effect heterogeneity by examining whether symptom-level information improves prediction of clinically meaningful outcomes."
["project_specific_aims"]=>
string(1633) "Aim 1. Characterize symptom-specific treatment effects, their trajectories and networks over time.
We will estimate differences between esketamine/ketamine, antipsychotics, and placebo in individual MADRS items and symptom domains over acute treatment, examining magnitude/timing, baseline influences (e.g., medical conditions),29 and cross-trial consistency. Network analysis will assess changes in symptom relationships/centrality and their link to outcomes. Hypothesis: Improvement will vary in magnitude and timing across symptoms, adding detail beyond total MADRS change. Network analysis is exploratory.
Aim 2. Determine whether early symptom-specific changes improve prediction of subsequent response beyond total depression severity.
We will compare models predicting response/remission using baseline characteristics and early total MADRS change versus models adding early individual symptom/domain changes, testing whether symptom-level data improve prediction. We will also examine heterogeneity in early symptomatic response. Hypothesis: Early symptom-specific changes add predictive value beyond baseline and total severity change.
Aim 3. Explore the relationship between symptom improvement and functional recovery.
Where available, we will examine correspondence between symptom improvement and functional/quality-of-life outcomes. We will also assess effects on comorbid conditions, including substance use. Hypothesis: Symptom and functional improvement will correlate but not fully align,30,31 with symptom-level data clarifying differences in functional outcomes."
["project_study_design"]=>
array(2) {
["value"]=>
string(7) "meta_an"
["label"]=>
string(52) "Meta-analysis (analysis of multiple trials together)"
}
["project_purposes"]=>
array(4) {
[0]=>
array(2) {
["value"]=>
string(56) "new_research_question_to_examine_treatment_effectiveness"
["label"]=>
string(114) "New research question to examine treatment effectiveness on secondary endpoints and/or within subgroup populations"
}
[1]=>
array(2) {
["value"]=>
string(22) "participant_level_data"
["label"]=>
string(36) "Participant-level data meta-analysis"
}
[2]=>
array(2) {
["value"]=>
string(37) "participant_level_data_only_from_yoda"
["label"]=>
string(51) "Meta-analysis using only data from the YODA Project"
}
[3]=>
array(2) {
["value"]=>
string(50) "research_on_clinical_prediction_or_risk_prediction"
["label"]=>
string(50) "Research on clinical prediction or risk prediction"
}
}
["project_research_methods"]=>
string(1656) "Trial eligibility criteria:
1. Randomized, double-blind, placebo-controlled clinical trials and open label trials evaluating esketamine/ketamine and/or antipsychotic medications (risperidone and quetiapine) for TRD.
2. Adult participants aged 18 years or older.
3. Availability of individual participant-level data.
4. Availability of symptom-level data on depressive symptoms at baseline and at least one time post-baseline.
The final list of eligible trials will be based on the requested YODA datasets and supporting documentation.
Participant eligibility criteria:
We will include individual participant data from adults with TRD who participated in eligible randomized controlled trials and open label trials of esketamine/ketamine and/or antipsychotic medication. Participants must have data on depression symptoms using the MADRS. Additional eligibility criteria will depend on the populations and treatment designs of the included trials and the availability of relevant outcome data.
Outcome-specific analyses will include participants with the data required for the relevant analysis. Participants without observed outcomes will be accounted for in longitudinal models adjusting for missing data using appropriate methods (e.g., multiple imputation, shared parameter models, sensitivity analysis, etc.).
The eligibility criteria for Aim 2 will additionally require the data necessary to define early symptom changes and subsequent response or remission. Aim 3 will include participants from trials with suitable functional or quality-of-life measures.
"
["project_main_outcome_measure"]=>
string(1999) "Primary outcomes
The primary symptom-level outcomes will be changes in individual MADRS17,19 items from baseline across available postbaseline assessments. Prespecified symptom domains may also be evaluated if their composition can be justified clinically and supported by the available data.
The primary prediction outcomes will be subsequent treatment response (at least 50% reduction) and remission (MADRS score of ≤10), defined using prespecified criteria consistent with established clinical definitions and the available trial data.
Early symptom changes will be evaluated as predictors of subsequent outcomes. The primary comparison will be between a reference model containing baseline characteristics and early total MADRS change and an expanded model that additionally incorporates symptom-specific changes.
The timing of early predictors and subsequent outcomes will be prespecified to ensure that predictors precede the outcomes being predicted.
Secondary outcomes
Secondary outcomes will include:
- Total MADRS change over time.
- Consistency of symptom-specific treatment effects across trials.
- Predictive performance for subsequent response and remission using alternative prespecified definitions, where appropriate.
- Functional impairment and health-related quality of life, where suitable measures are available.
- Recovery in other domains (e.g., substance use, anxiety symptoms, neurocognitive measures) where appropriate measures are available.
- Concordance and discordance between symptom response and functional improvement.
- Change in symptoms network measures, including different centrality measures for specific symptoms, network comparison tests, network intervention analysis.35,36
Potential functional measures include the Sheehan Disability Scale37,38 and EQ-5D,39 subject to confirmation of availability and comparability in the requested trials.
"
["project_main_predictor_indep"]=>
string(478) "Main Predictor
Randomized treatment assignments (esketamine/ketamine or antipsychotic medication versus placebo) will be the main predictor in analyses of treatment effects in RCTs. Further analyses will confirm the effects in open-label trials.
For the prediction analyses, early changes in total MADRS scores and individual MADRS items or prespecified symptom domains will be the primary predictors of subsequent clinical response and remission.
"
["project_other_variables_interest"]=>
string(781) "Potential baseline covariates include:
- Age and sex.
- Baseline MADRS total score and symptom-level scores.
- Relevant demographic characteristics available across trials.
- Baseline clinical characteristics and depression history, where harmonizable.
- Type of active treatment (esketamine/ketamine, risperidone, quetiapine) and concomitant medications/therapy.
- Trial identifier and trial design characteristics.
- Background antidepressant treatment and dosing regimen, where relevant.
The final covariate set will be prespecified based on clinical rationale, availability, and comparability across trials. Variables will not be included solely because they are statistically significant in preliminary analyses.
"
["project_stat_analysis_plan"]=>
string(5002) "General statistical principles:
Analyses will account for the multi-trial structure and repeated measurements within participants. Trial effects will be handled using fixed or random effects as appropriate to the analysis and the number and characteristics of available trials.
Continuous outcomes will be summarized using means, standard deviations, medians, interquartile ranges, and graphical distributions as appropriate. Binary outcomes will be summarized using counts and percentages.
Treatment effects, regression coefficients, predictive performance measures, and other estimates will be reported with confidence intervals. Interpretation will emphasize effect sizes, uncertainty, clinical relevance, and consistency across trials.
Descriptive network analysis (centrality, density, components, network comparison tests, network intervention analysis) will examine evolution of symptom constellations from before treatment to post-treatment and response to treatments.
Aim 1: Symptom-specific treatment effects:
Longitudinal mixed-effects models will estimate differences between esketamine/ketamine and placebo and antipsychotic medications and placebo in symptom-specific changes over time. Models will account for baseline symptom severity, repeated observations within participants, and trial differences.
Treatment-by-time interactions will be used to characterize differences in the timing of improvement. Symptom domains will be prespecified where feasible, with additional item-level analyses considered exploratory.
Sensitivity analyses will examine alternative assessment windows and the influence of individual trials. Multiplicity arising from multiple symptoms and time points will be addressed through prespecification of primary contrasts and appropriate interpretation of secondary analyses.
Aim 2: Incremental prediction of subsequent response and remission:
We will compare two nested prediction models.
Reference model: Baseline clinical characteristics and early change in total MADRS score.
Expanded model: The reference model plus early changes in individual MADRS items or prespecified symptom domains.
The models will be evaluated for subsequent response and remission using appropriate measures of discrimination, calibration, and prediction error. The primary assessment will be whether the expanded model improves predictive performance sufficiently to support the additional complexity of symptom-level assessment.
Internal validation will be used to assess optimism and overfitting. Where the number and structure of available trials permit, trial-level validation will be considered to evaluate the transportability of prediction across studies. Additionally, the results will be confirmed using data from open label trials. The analysis will account for the multi-trial.
Individual participant heterogeneity in responses will be examined using subgroup analyses of specified clinical and demographic groups as well as appropriate statistical modeling approaches in which the PI has experience.40
We will also examine whether the relationship between early symptom changes and subsequent outcomes differs by randomized treatment assignment and type of treatment (esketamine/ketamine vs. antipsychotics).
Aim 3: Symptom improvement and functional recovery:
If suitable functional, quality-of-life and/or comorbid symptom outcomes are available, we will examine their association with changes in total and symptom-specific MADRS scores.
We will define clinically interpretable categories of symptom response and functional improvement using prespecified criteria appropriate to each measure. We will estimate the proportion of participants with concordant improvement and discordant outcomes, including symptom response without corresponding functional improvement.
Longitudinal models will evaluate whether early symptom-specific changes are associated with subsequent functional outcomes, accounting for baseline functioning, trial differences, and relevant clinical characteristics where available.
Results will be reported separately when differences in measures or assessment schedules preclude pooling.
Missing data and sensitivity analyses:
We will describe missingness by trial, treatment group, assessment, and outcome. The primary handling of missing outcomes will be selected after examining the data structure, missing data patterns and the assumptions required by the relevant models.
Sensitivity analyses may include complete-case analyses, and leave-one-trial-out analyses, multiple imputation where feasible and sensitivity analysis.
We will also assess whether findings are robust to restricting analyses to trials with comparable outcome definitions and assessment schedules.
"
["project_software_used"]=>
array(3) {
[0]=>
array(2) {
["value"]=>
string(1) "r"
["label"]=>
string(1) "R"
}
[1]=>
array(2) {
["value"]=>
string(7) "rstudio"
["label"]=>
string(7) "RStudio"
}
[2]=>
array(2) {
["value"]=>
string(5) "stata"
["label"]=>
string(5) "STATA"
}
}
["project_timeline"]=>
string(1130) "The anticipated timeline is approximately 12 months following approval and access to the requested data.
- Months 1–2: Review trial documentation, data dictionaries, and available measures; finalize the data harmonization and statistical analysis plans. We will also evaluate data quality, and characterize outcome availability and missingness.
- Months 3–6: Conduct the primary symptom-specific treatment-effect analyses and prediction analyses.
- Months 7–9: Conduct functional-outcome analyses where feasible and complete sensitivity analyses. Prepare tables, figures, and manuscript drafts
- Months 10-12: Finalize the manuscripts and disseminate findings.
Data preparation and analysis are expected to be completed within 12 months, although additional time may be needed if harmonizing outcome measures across trials proves more complex than anticipated. If necessary, an extension will be requested. The overall timeline may be adjusted depending on data access, the availability and completeness of trial documentation, and the complexity of harmonizing data across trials.
"
["project_dissemination_plan"]=>
string(788) "Findings will be disseminated through peer-reviewed scientific publications and presentations at relevant national and international conferences. Potential journal venues are JAMA Psychiatry, American Journal of Psychiatry, JAMA Network open, and Journal of Clinical Psychiatry. Potential venues to present the results are Annual meeting of the American Psychiatric Association and Psych Conference. Results will be reported transparently, including null findings, uncertainty in estimates, limitations in outcome availability, and the distinction between exploratory and validated predictive findings.
The study will follow applicable YODA data-use requirements and publication policies. Results will be presented in aggregate, without identifying individual participants.
"
["project_bibliography"]=>
string(10548) "
- U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. PR Newswire. https://www.prnewswire.com/news-releases/fda-approves-new-nasal-spray-medication-for-treatment-resistant-depression-available-only-at-a-certified-doctors-office-or-clinic-300807354.html
- Administration. USFaD. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray: Prescribing information. 2025.
- Janik A, Qiu X, Lane R, et al. Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. Sep 1 2025;82(9):877-887. doi:10.1001/jamapsychiatry.2025.1317
- Mungo A, Hein M. [The efficacy of esketamine in resistant major depressive disorder: A systematic review of the literature]. Encephale. Aug 2022;48(4):455-461. L’efficacité de l’eskétamine dans le trouble dépressif majeur résistant : une revue systématique de la littérature. doi:10.1016/j.encep.2021.12.002
- Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol. Oct 1 2019;22(10):616-630. doi:10.1093/ijnp/pyz039
- Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. Feb 1 2018;75(2):139-148. doi:10.1001/jamapsychiatry.2017.3739
- Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. Jun 1 2019;176(6):428-438. doi:10.1176/appi.ajp.2019.19020172
- Zaki N, Chen LN, Lane R, et al. Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. Int J Neuropsychopharmacol. Jun 6 2025;28(6)doi:10.1093/ijnp/pyaf027
- d’Andrea G, Cavallotto C, Pettorruso M, et al. Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group. Psychiatry Res. Oct 2025;352:116655. doi:10.1016/j.psychres.2025.116655
- Floden L, Hudgens S, Jamieson C, et al. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant. CNS Drugs. Jun 2022;36(6):649-658. doi:10.1007/s40263-022-00916-2
- Naudet F, Pellen C, Fodor LA, et al. Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials. BMC Med. Nov 28 2025;23(1):677. doi:10.1186/s12916-025-04435-x
- Vázquez GH, Bahji A, Undurraga J, Tondo L, Baldessarini RJ. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. J Psychopharmacol. Aug 2021;35(8):890-900. doi:10.1177/02698811211013579
- Fountoulakis KN, Saitis A, Schatzberg AF. Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. Am J Psychiatry. Mar 1 2025;182(3):259-275. doi:10.1176/appi.ajp.20240515
- Bai B, Li Y, Chen X, et al. The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis. BMC Psychiatry. Apr 5 2025;25(1):338. doi:10.1186/s12888-025-06783-7
- Eckert D, Kasper S. Beyond first-line antidepressants: lithium, quetiapine, or esketamine? Integrating meta-analyses and preliminary head-to-head evidence. World J Biol Psychiatry. Mar 2026;27(3):200-211. doi:10.1080/15622975.2026.2617195
- Khalid R, Elbashir G, Hassan A, Abdulbagi M. Comparative Augmentative Efficacy of Second-Generation Antipsychotics in Adult Treatment-Resistant Depression: A Systematic Review. Cureus. May 2026;18(5):e109712. doi:10.7759/cureus.109712
- Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. The British journal of psychiatry. 1979;134(4):382-389.
- Hawley C, Gale T, Sivakumaran T, group HNR. Defining remission by cut off score on the MADRS: selecting the optimal value. Journal of affective disorders. 2002;72(2):177-184.
- Zimmerman M, Posternak MA, Chelminski I. Defining remission on the Montgomery-Asberg depression rating scale. Journal of Clinical Psychiatry. 2004;65(2):163-168.
- Komulainen K, Airaksinen J, Savelieva K, et al. Network dynamics of depressive symptoms in antidepressant medication treatment: secondary analysis of eight clinical trials. Mol Psychiatry. Jul 2021;26(7):3328-3335. doi:10.1038/s41380-020-00884-3
- Chekroud AM, Gueorguieva R, Krumholz HM, Trivedi MH, Krystal JH, McCarthy G. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. JAMA Psychiatry. Apr 1 2017;74(4):370-378. doi:10.1001/jamapsychiatry.2017.0025
- Fournier JC, DeRubeis RJ, Hollon SD, Gallop R, Shelton RC, Amsterdam JD. Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy. Behav Res Ther. Jul 2013;51(7):392-8. doi:10.1016/j.brat.2013.03.010
- Jha MK, Minhajuddin A, South C, Rush AJ, Trivedi MH. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. Am J Psychiatry. May 1 2019;176(5):358-366. doi:10.1176/appi.ajp.2018.18030355
- Huc M, Siddiqi S, Myers M, et al. Sex differences in placebo and antidepressant response to intranasal esketamine for treatment-resistant depression. Mol Psychiatry. Jul 2026;31(7):3674-3682. doi:10.1038/s41380-026-03493-8
- de Vries YA, Roest AM, Bos EH, Burgerhof JGM, van Loo HM, de Jonge P. Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis. Br J Psychiatry. Jan 2019;214(1):4-10. doi:10.1192/bjp.2018.122
- Snippe E, Doornbos B, Schoevers RA, Wardenaar KJ, Wichers M. Individual and common patterns in the order of symptom improvement during outpatient treatment for major depression. J Affect Disord. Jul 1 2021;290:81-88. doi:10.1016/j.jad.2021.04.097
- Hossein S, Rengasamy M, Uzamere A, et al. Effects of ketamine on individual symptoms and symptom networks of depression in a randomised controlled trial of ketamine for treatment-resistant depression. Br J Psychiatry. Nov 2025;227(5):756-765. doi:10.1192/bjp.2024.276
- Landrum RE, Raines AM, Harvey PD, Banov MD, Saulnier KG, Moore MB. Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression: An Exploratory Retrospective Analysis. J Clin Psychopharmacol. Nov-Dec 01 2025;45(6):562-569. doi:10.1097/JCP.0000000000002060
- Mojtabai R, Amin-Esmaeili M, Spivak S, Olfson M. Use of Non-Psychiatric Medications With Potential Depressive Symptom Side Effects and Level of Depressive Symptoms in Major Depressive Disorder. J Clin Psychiatry. May 24 2023;84(4)doi:10.4088/JCP.22m14705
- Mojtabai R. Residual symptoms and impairment in major depression in the community. Am J Psychiatry. Oct 2001;158(10):1645-51. doi:10.1176/appi.ajp.158.10.1645
- Mojtabai R. Impairment in major depression: implications for diagnosis. Compr Psychiatry. May-Jun 2001;42(3):206-12. doi:10.1053/comp.2001.23142
- Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med. Feb 28 2017;36(5):855-875. doi:10.1002/sim.7141
- Abo-Zaid G, Guo B, Deeks JJ, et al. Individual participant data meta-analyses should not ignore clustering. J Clin Epidemiol. Aug 2013;66(8):865-873.e4. doi:10.1016/j.jclinepi.2012.12.017
- Debray TP, Moons KG, van Valkenhoef G, et al. Get real in individual participant data (IPD) meta-analysis: a review of the methodology. Res Synth Methods. Dec 2015;6(4):293-309. doi:10.1002/jrsm.1160
- Bodner N, Bringmann L, Tuerlinckx F, de Jonge P, Ceulemans E. ConNEcT: A Novel Network Approach for Investigating the Co-occurrence of Binary Psychopathological Symptoms Over Time. Psychometrika. Mar 2022;87(1):107-132. doi:10.1007/s11336-021-09765-2
- Bringmann LF, Vissers N, Wichers M, et al. A network approach to psychopathology: new insights into clinical longitudinal data. PLoS One. 2013;8(4):e60188. doi:10.1371/journal.pone.0060188
- Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. Jun 1996;11 Suppl 3:89-95. doi:10.1097/00004850-199606003-00015
- Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. Mar 2008;23(2):70-83. doi:10.1097/YIC.0b013e3282f2b4d6
- The EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. Dec 1990;16(3):199-208. doi:10.1016/0168-8510(90)90421-9
- Susukida R, Amin-Esmaeili M, Badillo-Goicoechea E, et al. Application of Causal Forest Model to Examine Treatment Effect Heterogeneity in Substance Use Disorder Psychosocial Treatments. Int J Methods Psychiatr Res. Mar 2025;34(1):e70011. doi:10.1002/mpr.70011
"
["project_suppl_material"]=>
bool(false)
["project_coi"]=>
array(3) {
[0]=>
array(1) {
["file_coi"]=>
array(21) {
["ID"]=>
int(20315)
["id"]=>
int(20315)
["title"]=>
string(16) "Mojtabai-COI.pdf"
["filename"]=>
string(16) "Mojtabai-COI.pdf"
["filesize"]=>
int(35803)
["url"]=>
string(65) "https://yoda.yale.edu/wp-content/uploads/2026/10/Mojtabai-COI.pdf"
["link"]=>
string(62) "https://yoda.yale.edu/data-request/2026-1152/mojtabai-coi-pdf/"
["alt"]=>
string(0) ""
["author"]=>
string(4) "2637"
["description"]=>
string(0) ""
["caption"]=>
string(0) ""
["name"]=>
string(16) "mojtabai-coi-pdf"
["status"]=>
string(7) "inherit"
["uploaded_to"]=>
int(20300)
["date"]=>
string(19) "2026-10-21 21:04:23"
["modified"]=>
string(19) "2026-10-21 21:04:29"
["menu_order"]=>
int(0)
["mime_type"]=>
string(15) "application/pdf"
["type"]=>
string(11) "application"
["subtype"]=>
string(3) "pdf"
["icon"]=>
string(62) "https://yoda.yale.edu/wp/wp-includes/images/media/document.png"
}
}
[1]=>
array(1) {
["file_coi"]=>
array(21) {
["ID"]=>
int(20316)
["id"]=>
int(20316)
["title"]=>
string(20) "Aminesmaeili-COI.pdf"
["filename"]=>
string(20) "Aminesmaeili-COI.pdf"
["filesize"]=>
int(31160)
["url"]=>
string(69) "https://yoda.yale.edu/wp-content/uploads/2026/10/Aminesmaeili-COI.pdf"
["link"]=>
string(66) "https://yoda.yale.edu/data-request/2026-1152/aminesmaeili-coi-pdf/"
["alt"]=>
string(0) ""
["author"]=>
string(4) "2637"
["description"]=>
string(0) ""
["caption"]=>
string(0) ""
["name"]=>
string(20) "aminesmaeili-coi-pdf"
["status"]=>
string(7) "inherit"
["uploaded_to"]=>
int(20300)
["date"]=>
string(19) "2026-10-21 21:04:25"
["modified"]=>
string(19) "2026-10-21 21:04:29"
["menu_order"]=>
int(0)
["mime_type"]=>
string(15) "application/pdf"
["type"]=>
string(11) "application"
["subtype"]=>
string(3) "pdf"
["icon"]=>
string(62) "https://yoda.yale.edu/wp/wp-includes/images/media/document.png"
}
}
[2]=>
array(1) {
["file_coi"]=>
array(21) {
["ID"]=>
int(20317)
["id"]=>
int(20317)
["title"]=>
string(16) "Susukida-COI.pdf"
["filename"]=>
string(16) "Susukida-COI.pdf"
["filesize"]=>
int(31195)
["url"]=>
string(65) "https://yoda.yale.edu/wp-content/uploads/2026/10/Susukida-COI.pdf"
["link"]=>
string(62) "https://yoda.yale.edu/data-request/2026-1152/susukida-coi-pdf/"
["alt"]=>
string(0) ""
["author"]=>
string(4) "2637"
["description"]=>
string(0) ""
["caption"]=>
string(0) ""
["name"]=>
string(16) "susukida-coi-pdf"
["status"]=>
string(7) "inherit"
["uploaded_to"]=>
int(20300)
["date"]=>
string(19) "2026-10-21 21:04:27"
["modified"]=>
string(19) "2026-10-21 21:04:29"
["menu_order"]=>
int(0)
["mime_type"]=>
string(15) "application/pdf"
["type"]=>
string(11) "application"
["subtype"]=>
string(3) "pdf"
["icon"]=>
string(62) "https://yoda.yale.edu/wp/wp-includes/images/media/document.png"
}
}
}
["data_use_agreement_training"]=>
bool(true)
["human_research_protection_training"]=>
bool(true)
["certification"]=>
bool(true)
["search_order"]=>
string(1) "0"
["project_send_email_updates"]=>
bool(false)
["project_publ_available"]=>
bool(true)
["project_year_access"]=>
string(0) ""
["project_rep_publ"]=>
bool(false)
["project_assoc_data"]=>
array(0) {
}
["project_due_dil_assessment"]=>
bool(false)
["project_title_link"]=>
array(21) {
["ID"]=>
int(19765)
["id"]=>
int(19765)
["title"]=>
string(28) "Data Request Approved Notice"
["filename"]=>
string(32) "Data-Request-Approved-Notice.pdf"
["filesize"]=>
int(195663)
["url"]=>
string(81) "https://yoda.yale.edu/wp-content/uploads/2026/07/Data-Request-Approved-Notice.pdf"
["link"]=>
string(77) "https://yoda.yale.edu/data-request/2026-0640/data-request-approved-notice-72/"
["alt"]=>
string(0) ""
["author"]=>
string(4) "1885"
["description"]=>
string(0) ""
["caption"]=>
string(0) ""
["name"]=>
string(31) "data-request-approved-notice-72"
["status"]=>
string(7) "inherit"
["uploaded_to"]=>
int(19689)
["date"]=>
string(19) "2026-08-06 16:54:58"
["modified"]=>
string(19) "2026-08-06 16:54:58"
["menu_order"]=>
int(0)
["mime_type"]=>
string(15) "application/pdf"
["type"]=>
string(11) "application"
["subtype"]=>
string(3) "pdf"
["icon"]=>
string(62) "https://yoda.yale.edu/wp/wp-includes/images/media/document.png"
}
["project_review_link"]=>
bool(false)
["project_highlight_button"]=>
string(0) ""
["request_data_partner"]=>
string(0) ""
}
data partner
array(1) {
[0]=>
string(0) ""
}
pi country
array(0) {
}
pi affil
array(0) {
}
products
array(0) {
}
num of trials
array(1) {
[0]=>
string(1) "0"
}
res
array(1) {
[0]=>
string(1) "3"
}
General Information
How did you learn about the YODA Project?:
Colleague
Conflict of Interest
Request Clinical Trials
Associated Trial(s):
- NCT04599855 - A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
- NCT04338321 - A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)
- NCT03434041 - A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
- NCT02497287 - An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
- NCT02493868 - A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression
- NCT02918318 - A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression
- NCT01640080 - A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects With Treatment-Resistant Depression
- NCT03097133 - A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide
- NCT02133001 - A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Who Are Assessed to be at Imminent Risk for Suicide
- NCT03039192 - A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide
- NCT02422186 - A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression
- NCT01998958 - A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)
- NCT02418585 - A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
- NCT02417064 - A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression
- NCT01627782 - A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression
- NCT00044681 - A Study to Evaluate the Efficacy, Safety and Maintenance Effect of Risperidone Augmentation of SSRI Monotherapy in Young and Older Adult Patients With Unipolar Treatment-Resistant Depression
- NCT00095134 - A Double-Blind Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is not Responding to Standard Therapy
What type of data are you looking for?:
Individual Participant-Level Data, which includes Full CSR and all supporting documentation
Request Clinical Trials
Data Request Status
Status:
Approved Pending DUA Signature
Research Proposal
Project Title:
Symptom-Specific Changes and Prediction of Clinical Response in Esketamine/Ketamine and Antipsychotic Trials of Treatment-Resistant Depression
Scientific Abstract:
Background: Both esketamine/ketamine and antipsychotic medications are increasingly used in management of TRD. The efficacy of these treatments is commonly evaluated using changes in total depression severity scores. Total scores may obscure differences in treatment effects across individual symptoms and may not capture all clinically relevant dimensions of recovery. Whether early symptom-specific changes provide useful information about subsequent treatment outcomes beyond conventional total scores remains an important question.
Objective: To determine whether early symptom-level changes improve the prediction of subsequent clinical response and remission beyond total depression severity scores. Secondary objectives are to examine the relationship between symptom improvement and functional recovery, heterogeneity of symptom responses and examine the network of symptoms before and after treatment.
Study Design: One-stage individual participant data meta-analysis.
Participants: Adult participants in eligible randomized controlled trials and open-label trials.
Primary and Secondary Outcomes: The primary outcomes will be symptom-specific changes measured using individual items of the Montgomery--Asberg Depression Rating Scale (MADRS). Secondary outcomes include functional impairment, comorbidity and health-related quality of life, where comparable measures are available.
Statistical Analysis: Longitudinal mixed-effects models for predictive analysis, estimation of conditional average treatment effect for heterogeneity in symptom responses, network analysis of symptoms.
Brief Project Background and Statement of Project Significance:
Esketamine, a noncompetitive NMDA receptor antagonist, was FDA-approved in 2019 for use with an oral antidepressant in treatment-resistant depression (TRD), and in 2025 as monotherapy for TRD patients inadequately responsive to two antidepressants.1,2 Multiple randomized trials have evaluated esketamine for TRD.3-11 Several second-generation antipsychotics are also approved as adjunctive MDD treatments after inadequate antidepressant response.12-16 Most efficacy analyses rely on total MADRS score changes,3,5-8,12-16 with response/remission defined by prespecified severity thresholds.17-19 While clinically established, total scores can obscure differences in how patients' symptoms improve.
Depressive symptoms are heterogeneous: patients with similar reductions in total severity may differ markedly in mood, anhedonia, concentration, sleep, and appetite.20-23 Characterizing symptom-specific treatment effects may offer a more detailed picture of esketamine's clinical effects.
Prior work examined individual MADRS/PHQ-9 item changes in an esketamine TRD trial10 and sex differences in symptom-domain response.24 However, it remains unclear whether early symptom-specific changes add predictive information about subsequent response/remission beyond early changes in total severity, and whether this generalizes across trials. Symptom-level associations with outcomes do not necessarily indicate differential treatment effects--they may reflect general improvement, placebo response, baseline severity, or other prognostic factors. Analyses must separate prediction of outcomes from estimation of differential treatment effects. A related question is whether symptom improvement corresponds to functional recovery.
Some studies suggest individual symptom analysis adds little predictive value beyond early overall improvement in MDD generally,25,26 though patients vary substantially in which symptoms respond first.26 Symptom-specific response in TRD has rarely been studied. One IV ketamine study found the largest early effect on sadness, with suicidal symptom improvement emerging later.27 The study also found strengthened interrelationships among residual symptoms. Another found suicidal ideation and mood showed the largest response and appetite the least.28
Individual trials can evaluate symptom-specific effects but are limited by small samples, narrow treatment ranges, and inability to test reproducibility. An individual participant data meta-analysis of esketamine/ketamine and antipsychotic trials offers the chance to examine symptom-specific effects and trajectories in a larger, diverse population; test whether patterns are consistent across trials; and determine whether early symptom changes add predictive value beyond total depression scores in TRD. Combining participant- and trial-level data allows assessment of cross-study consistency, ruling out effects driven by specific populations or settings.
This study complements existing evaluations of average treatment efficacy and treatment-effect heterogeneity by examining whether symptom-level information improves prediction of clinically meaningful outcomes.
Specific Aims of the Project:
Aim 1. Characterize symptom-specific treatment effects, their trajectories and networks over time.
We will estimate differences between esketamine/ketamine, antipsychotics, and placebo in individual MADRS items and symptom domains over acute treatment, examining magnitude/timing, baseline influences (e.g., medical conditions),29 and cross-trial consistency. Network analysis will assess changes in symptom relationships/centrality and their link to outcomes. Hypothesis: Improvement will vary in magnitude and timing across symptoms, adding detail beyond total MADRS change. Network analysis is exploratory.
Aim 2. Determine whether early symptom-specific changes improve prediction of subsequent response beyond total depression severity.
We will compare models predicting response/remission using baseline characteristics and early total MADRS change versus models adding early individual symptom/domain changes, testing whether symptom-level data improve prediction. We will also examine heterogeneity in early symptomatic response. Hypothesis: Early symptom-specific changes add predictive value beyond baseline and total severity change.
Aim 3. Explore the relationship between symptom improvement and functional recovery.
Where available, we will examine correspondence between symptom improvement and functional/quality-of-life outcomes. We will also assess effects on comorbid conditions, including substance use. Hypothesis: Symptom and functional improvement will correlate but not fully align,30,31 with symptom-level data clarifying differences in functional outcomes.
Study Design:
Meta-analysis (analysis of multiple trials together)
What is the purpose of the analysis being proposed? Please select all that apply.:
New research question to examine treatment effectiveness on secondary endpoints and/or within subgroup populations
Participant-level data meta-analysis
Meta-analysis using only data from the YODA Project
Research on clinical prediction or risk prediction
Software Used:
R, RStudio, STATA
Data Source and Inclusion/Exclusion Criteria to be used to define the patient sample for your study:
Trial eligibility criteria:
1. Randomized, double-blind, placebo-controlled clinical trials and open label trials evaluating esketamine/ketamine and/or antipsychotic medications (risperidone and quetiapine) for TRD.
2. Adult participants aged 18 years or older.
3. Availability of individual participant-level data.
4. Availability of symptom-level data on depressive symptoms at baseline and at least one time post-baseline.
The final list of eligible trials will be based on the requested YODA datasets and supporting documentation.
Participant eligibility criteria:
We will include individual participant data from adults with TRD who participated in eligible randomized controlled trials and open label trials of esketamine/ketamine and/or antipsychotic medication. Participants must have data on depression symptoms using the MADRS. Additional eligibility criteria will depend on the populations and treatment designs of the included trials and the availability of relevant outcome data.
Outcome-specific analyses will include participants with the data required for the relevant analysis. Participants without observed outcomes will be accounted for in longitudinal models adjusting for missing data using appropriate methods (e.g., multiple imputation, shared parameter models, sensitivity analysis, etc.).
The eligibility criteria for Aim 2 will additionally require the data necessary to define early symptom changes and subsequent response or remission. Aim 3 will include participants from trials with suitable functional or quality-of-life measures.
Primary and Secondary Outcome Measure(s) and how they will be categorized/defined for your study:
Primary outcomes
The primary symptom-level outcomes will be changes in individual MADRS17,19 items from baseline across available postbaseline assessments. Prespecified symptom domains may also be evaluated if their composition can be justified clinically and supported by the available data.
The primary prediction outcomes will be subsequent treatment response (at least 50% reduction) and remission (MADRS score of <=10), defined using prespecified criteria consistent with established clinical definitions and the available trial data.
Early symptom changes will be evaluated as predictors of subsequent outcomes. The primary comparison will be between a reference model containing baseline characteristics and early total MADRS change and an expanded model that additionally incorporates symptom-specific changes.
The timing of early predictors and subsequent outcomes will be prespecified to ensure that predictors precede the outcomes being predicted.
Secondary outcomes
Secondary outcomes will include:
- Total MADRS change over time.
- Consistency of symptom-specific treatment effects across trials.
- Predictive performance for subsequent response and remission using alternative prespecified definitions, where appropriate.
- Functional impairment and health-related quality of life, where suitable measures are available.
- Recovery in other domains (e.g., substance use, anxiety symptoms, neurocognitive measures) where appropriate measures are available.
- Concordance and discordance between symptom response and functional improvement.
- Change in symptoms network measures, including different centrality measures for specific symptoms, network comparison tests, network intervention analysis.35,36
Potential functional measures include the Sheehan Disability Scale37,38 and EQ-5D,39 subject to confirmation of availability and comparability in the requested trials.
Main Predictor/Independent Variable and how it will be categorized/defined for your study:
Main Predictor
Randomized treatment assignments (esketamine/ketamine or antipsychotic medication versus placebo) will be the main predictor in analyses of treatment effects in RCTs. Further analyses will confirm the effects in open-label trials.
For the prediction analyses, early changes in total MADRS scores and individual MADRS items or prespecified symptom domains will be the primary predictors of subsequent clinical response and remission.
Other Variables of Interest that will be used in your analysis and how they will be categorized/defined for your study:
Potential baseline covariates include:
- Age and sex.
- Baseline MADRS total score and symptom-level scores.
- Relevant demographic characteristics available across trials.
- Baseline clinical characteristics and depression history, where harmonizable.
- Type of active treatment (esketamine/ketamine, risperidone, quetiapine) and concomitant medications/therapy.
- Trial identifier and trial design characteristics.
- Background antidepressant treatment and dosing regimen, where relevant.
The final covariate set will be prespecified based on clinical rationale, availability, and comparability across trials. Variables will not be included solely because they are statistically significant in preliminary analyses.
Statistical Analysis Plan:
General statistical principles:
Analyses will account for the multi-trial structure and repeated measurements within participants. Trial effects will be handled using fixed or random effects as appropriate to the analysis and the number and characteristics of available trials.
Continuous outcomes will be summarized using means, standard deviations, medians, interquartile ranges, and graphical distributions as appropriate. Binary outcomes will be summarized using counts and percentages.
Treatment effects, regression coefficients, predictive performance measures, and other estimates will be reported with confidence intervals. Interpretation will emphasize effect sizes, uncertainty, clinical relevance, and consistency across trials.
Descriptive network analysis (centrality, density, components, network comparison tests, network intervention analysis) will examine evolution of symptom constellations from before treatment to post-treatment and response to treatments.
Aim 1: Symptom-specific treatment effects:
Longitudinal mixed-effects models will estimate differences between esketamine/ketamine and placebo and antipsychotic medications and placebo in symptom-specific changes over time. Models will account for baseline symptom severity, repeated observations within participants, and trial differences.
Treatment-by-time interactions will be used to characterize differences in the timing of improvement. Symptom domains will be prespecified where feasible, with additional item-level analyses considered exploratory.
Sensitivity analyses will examine alternative assessment windows and the influence of individual trials. Multiplicity arising from multiple symptoms and time points will be addressed through prespecification of primary contrasts and appropriate interpretation of secondary analyses.
Aim 2: Incremental prediction of subsequent response and remission:
We will compare two nested prediction models.
Reference model: Baseline clinical characteristics and early change in total MADRS score.
Expanded model: The reference model plus early changes in individual MADRS items or prespecified symptom domains.
The models will be evaluated for subsequent response and remission using appropriate measures of discrimination, calibration, and prediction error. The primary assessment will be whether the expanded model improves predictive performance sufficiently to support the additional complexity of symptom-level assessment.
Internal validation will be used to assess optimism and overfitting. Where the number and structure of available trials permit, trial-level validation will be considered to evaluate the transportability of prediction across studies. Additionally, the results will be confirmed using data from open label trials. The analysis will account for the multi-trial.
Individual participant heterogeneity in responses will be examined using subgroup analyses of specified clinical and demographic groups as well as appropriate statistical modeling approaches in which the PI has experience.40
We will also examine whether the relationship between early symptom changes and subsequent outcomes differs by randomized treatment assignment and type of treatment (esketamine/ketamine vs. antipsychotics).
Aim 3: Symptom improvement and functional recovery:
If suitable functional, quality-of-life and/or comorbid symptom outcomes are available, we will examine their association with changes in total and symptom-specific MADRS scores.
We will define clinically interpretable categories of symptom response and functional improvement using prespecified criteria appropriate to each measure. We will estimate the proportion of participants with concordant improvement and discordant outcomes, including symptom response without corresponding functional improvement.
Longitudinal models will evaluate whether early symptom-specific changes are associated with subsequent functional outcomes, accounting for baseline functioning, trial differences, and relevant clinical characteristics where available.
Results will be reported separately when differences in measures or assessment schedules preclude pooling.
Missing data and sensitivity analyses:
We will describe missingness by trial, treatment group, assessment, and outcome. The primary handling of missing outcomes will be selected after examining the data structure, missing data patterns and the assumptions required by the relevant models.
Sensitivity analyses may include complete-case analyses, and leave-one-trial-out analyses, multiple imputation where feasible and sensitivity analysis.
We will also assess whether findings are robust to restricting analyses to trials with comparable outcome definitions and assessment schedules.
Narrative Summary:
This study will use individual participant data (IPD) from randomized, placebo-controlled and open label trials of esketamine/ketamine and antipsychotics for treatment-resistant depression to investigate whether examining changes in individual depressive symptoms provides clinically useful information beyond conventional total depression severity scores.
The study will evaluate whether early changes in individual symptoms improve the prediction of subsequent response and remission beyond baseline characteristics and early changes in total depression severity. Where comparable measures are available, the study will also examine whether symptom improvement corresponds to functional recovery.
The goal is to determine whether more detailed symptom-level information can enhance the evaluation of clinically meaningful treatment outcomes.
Project Timeline:
The anticipated timeline is approximately 12 months following approval and access to the requested data.
- Months 1--2: Review trial documentation, data dictionaries, and available measures; finalize the data harmonization and statistical analysis plans. We will also evaluate data quality, and characterize outcome availability and missingness.
- Months 3--6: Conduct the primary symptom-specific treatment-effect analyses and prediction analyses.
- Months 7--9: Conduct functional-outcome analyses where feasible and complete sensitivity analyses. Prepare tables, figures, and manuscript drafts
- Months 10-12: Finalize the manuscripts and disseminate findings.
Data preparation and analysis are expected to be completed within 12 months, although additional time may be needed if harmonizing outcome measures across trials proves more complex than anticipated. If necessary, an extension will be requested. The overall timeline may be adjusted depending on data access, the availability and completeness of trial documentation, and the complexity of harmonizing data across trials.
Dissemination Plan:
Findings will be disseminated through peer-reviewed scientific publications and presentations at relevant national and international conferences. Potential journal venues are JAMA Psychiatry, American Journal of Psychiatry, JAMA Network open, and Journal of Clinical Psychiatry. Potential venues to present the results are Annual meeting of the American Psychiatric Association and Psych Conference. Results will be reported transparently, including null findings, uncertainty in estimates, limitations in outcome availability, and the distinction between exploratory and validated predictive findings.
The study will follow applicable YODA data-use requirements and publication policies. Results will be presented in aggregate, without identifying individual participants.
Bibliography:
- U.S. Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. PR Newswire. https://www.prnewswire.com/news-releases/fda-approves-new-nasal-spray-medication-for-treatment-resistant-depression-available-only-at-a-certified-doctors-office-or-clinic-300807354.html
- Administration. USFaD. U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray: Prescribing information. 2025.
- Janik A, Qiu X, Lane R, et al. Esketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. Sep 1 2025;82(9):877-887. doi:10.1001/jamapsychiatry.2025.1317
- Mungo A, Hein M. [The efficacy of esketamine in resistant major depressive disorder: A systematic review of the literature]. Encephale. Aug 2022;48(4):455-461. L'efficacité de l'eskétamine dans le trouble dépressif majeur résistant : une revue systématique de la littérature. doi:10.1016/j.encep.2021.12.002
- Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol. Oct 1 2019;22(10):616-630. doi:10.1093/ijnp/pyz039
- Daly EJ, Singh JB, Fedgchin M, et al. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. Feb 1 2018;75(2):139-148. doi:10.1001/jamapsychiatry.2017.3739
- Popova V, Daly EJ, Trivedi M, et al. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry. Jun 1 2019;176(6):428-438. doi:10.1176/appi.ajp.2019.19020172
- Zaki N, Chen LN, Lane R, et al. Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study. Int J Neuropsychopharmacol. Jun 6 2025;28(6)doi:10.1093/ijnp/pyaf027
- d’Andrea G, Cavallotto C, Pettorruso M, et al. Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group. Psychiatry Res. Oct 2025;352:116655. doi:10.1016/j.psychres.2025.116655
- Floden L, Hudgens S, Jamieson C, et al. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant. CNS Drugs. Jun 2022;36(6):649-658. doi:10.1007/s40263-022-00916-2
- Naudet F, Pellen C, Fodor LA, et al. Efficacy and safety of esketamine for “treatment resistant depression”: registered report for a systematic review with an individual patient data meta-analysis of randomized, double-blind, placebo-controlled trials. BMC Med. Nov 28 2025;23(1):677. doi:10.1186/s12916-025-04435-x
- Vázquez GH, Bahji A, Undurraga J, Tondo L, Baldessarini RJ. Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium. J Psychopharmacol. Aug 2021;35(8):890-900. doi:10.1177/02698811211013579
- Fountoulakis KN, Saitis A, Schatzberg AF. Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. Am J Psychiatry. Mar 1 2025;182(3):259-275. doi:10.1176/appi.ajp.20240515
- Bai B, Li Y, Chen X, et al. The augmentative efficacy of second-generation anti-psychotics (SGA) to anti-depressants in treating treatment-resistant depression: a network meta-regression analysis. BMC Psychiatry. Apr 5 2025;25(1):338. doi:10.1186/s12888-025-06783-7
- Eckert D, Kasper S. Beyond first-line antidepressants: lithium, quetiapine, or esketamine? Integrating meta-analyses and preliminary head-to-head evidence. World J Biol Psychiatry. Mar 2026;27(3):200-211. doi:10.1080/15622975.2026.2617195
- Khalid R, Elbashir G, Hassan A, Abdulbagi M. Comparative Augmentative Efficacy of Second-Generation Antipsychotics in Adult Treatment-Resistant Depression: A Systematic Review. Cureus. May 2026;18(5):e109712. doi:10.7759/cureus.109712
- Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. The British journal of psychiatry. 1979;134(4):382-389.
- Hawley C, Gale T, Sivakumaran T, group HNR. Defining remission by cut off score on the MADRS: selecting the optimal value. Journal of affective disorders. 2002;72(2):177-184.
- Zimmerman M, Posternak MA, Chelminski I. Defining remission on the Montgomery-Asberg depression rating scale. Journal of Clinical Psychiatry. 2004;65(2):163-168.
- Komulainen K, Airaksinen J, Savelieva K, et al. Network dynamics of depressive symptoms in antidepressant medication treatment: secondary analysis of eight clinical trials. Mol Psychiatry. Jul 2021;26(7):3328-3335. doi:10.1038/s41380-020-00884-3
- Chekroud AM, Gueorguieva R, Krumholz HM, Trivedi MH, Krystal JH, McCarthy G. Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. JAMA Psychiatry. Apr 1 2017;74(4):370-378. doi:10.1001/jamapsychiatry.2017.0025
- Fournier JC, DeRubeis RJ, Hollon SD, Gallop R, Shelton RC, Amsterdam JD. Differential change in specific depressive symptoms during antidepressant medication or cognitive therapy. Behav Res Ther. Jul 2013;51(7):392-8. doi:10.1016/j.brat.2013.03.010
- Jha MK, Minhajuddin A, South C, Rush AJ, Trivedi MH. Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. Am J Psychiatry. May 1 2019;176(5):358-366. doi:10.1176/appi.ajp.2018.18030355
- Huc M, Siddiqi S, Myers M, et al. Sex differences in placebo and antidepressant response to intranasal esketamine for treatment-resistant depression. Mol Psychiatry. Jul 2026;31(7):3674-3682. doi:10.1038/s41380-026-03493-8
- de Vries YA, Roest AM, Bos EH, Burgerhof JGM, van Loo HM, de Jonge P. Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis. Br J Psychiatry. Jan 2019;214(1):4-10. doi:10.1192/bjp.2018.122
- Snippe E, Doornbos B, Schoevers RA, Wardenaar KJ, Wichers M. Individual and common patterns in the order of symptom improvement during outpatient treatment for major depression. J Affect Disord. Jul 1 2021;290:81-88. doi:10.1016/j.jad.2021.04.097
- Hossein S, Rengasamy M, Uzamere A, et al. Effects of ketamine on individual symptoms and symptom networks of depression in a randomised controlled trial of ketamine for treatment-resistant depression. Br J Psychiatry. Nov 2025;227(5):756-765. doi:10.1192/bjp.2024.276
- Landrum RE, Raines AM, Harvey PD, Banov MD, Saulnier KG, Moore MB. Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression: An Exploratory Retrospective Analysis. J Clin Psychopharmacol. Nov-Dec 01 2025;45(6):562-569. doi:10.1097/JCP.0000000000002060
- Mojtabai R, Amin-Esmaeili M, Spivak S, Olfson M. Use of Non-Psychiatric Medications With Potential Depressive Symptom Side Effects and Level of Depressive Symptoms in Major Depressive Disorder. J Clin Psychiatry. May 24 2023;84(4)doi:10.4088/JCP.22m14705
- Mojtabai R. Residual symptoms and impairment in major depression in the community. Am J Psychiatry. Oct 2001;158(10):1645-51. doi:10.1176/appi.ajp.158.10.1645
- Mojtabai R. Impairment in major depression: implications for diagnosis. Compr Psychiatry. May-Jun 2001;42(3):206-12. doi:10.1053/comp.2001.23142
- Burke DL, Ensor J, Riley RD. Meta-analysis using individual participant data: one-stage and two-stage approaches, and why they may differ. Stat Med. Feb 28 2017;36(5):855-875. doi:10.1002/sim.7141
- Abo-Zaid G, Guo B, Deeks JJ, et al. Individual participant data meta-analyses should not ignore clustering. J Clin Epidemiol. Aug 2013;66(8):865-873.e4. doi:10.1016/j.jclinepi.2012.12.017
- Debray TP, Moons KG, van Valkenhoef G, et al. Get real in individual participant data (IPD) meta-analysis: a review of the methodology. Res Synth Methods. Dec 2015;6(4):293-309. doi:10.1002/jrsm.1160
- Bodner N, Bringmann L, Tuerlinckx F, de Jonge P, Ceulemans E. ConNEcT: A Novel Network Approach for Investigating the Co-occurrence of Binary Psychopathological Symptoms Over Time. Psychometrika. Mar 2022;87(1):107-132. doi:10.1007/s11336-021-09765-2
- Bringmann LF, Vissers N, Wichers M, et al. A network approach to psychopathology: new insights into clinical longitudinal data. PLoS One. 2013;8(4):e60188. doi:10.1371/journal.pone.0060188
- Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. Jun 1996;11 Suppl 3:89-95. doi:10.1097/00004850-199606003-00015
- Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. Mar 2008;23(2):70-83. doi:10.1097/YIC.0b013e3282f2b4d6
- The EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. Dec 1990;16(3):199-208. doi:10.1016/0168-8510(90)90421-9
- Susukida R, Amin-Esmaeili M, Badillo-Goicoechea E, et al. Application of Causal Forest Model to Examine Treatment Effect Heterogeneity in Substance Use Disorder Psychosocial Treatments. Int J Methods Psychiatr Res. Mar 2025;34(1):e70011. doi:10.1002/mpr.70011